Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Liver Int ; 37(5): 653-661, 2017 05.
Article in English | MEDLINE | ID: mdl-27782373

ABSTRACT

BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were ≥65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged <65 years and 97.7% (130/133) of those ≥65 years. Diabetes was the most common comorbidity in patients ≥65 years compared to younger patients (26.3% vs 12.4% P<.003). The most common adverse event (AE) in elderly patients was a grade 2 anaemia (35.3% vs 19.9% P<.004). CONCLUSIONS: Sofosbuvir/simeprevir plus a daily flat dose of RBV 800 mg for 12 weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis.


Subject(s)
Antiviral Agents/administration & dosage , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/drug therapy , Ribavirin/administration & dosage , Simeprevir/administration & dosage , Sofosbuvir/administration & dosage , Adult , Aged , Aged, 80 and over , Anemia/etiology , Antiviral Agents/adverse effects , Drug Administration Schedule , Drug Therapy, Combination , Female , Hepacivirus/genetics , Humans , Italy , Liver Cirrhosis/virology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Ribavirin/adverse effects , Simeprevir/adverse effects , Sofosbuvir/adverse effects , Sustained Virologic Response
2.
Ann Hepatol ; 14(5): 756-61, 2015.
Article in English | MEDLINE | ID: mdl-26256907

ABSTRACT

Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cholestasis/chemically induced , Hepacivirus/drug effects , Hepatitis C/chemically induced , Lymphoma, Large B-Cell, Diffuse/drug therapy , Rituximab/adverse effects , Virus Activation/drug effects , Aged , Antiviral Agents/therapeutic use , Biopsy , Cholestasis/diagnosis , Cholestasis/drug therapy , Cholestasis/virology , Hepacivirus/pathogenicity , Hepatitis C/diagnosis , Hepatitis C/drug therapy , Hepatitis C/virology , Humans , Male , Time Factors , Treatment Outcome
3.
Ann Hepatol ; 13(4): 376-85, 2014.
Article in English | MEDLINE | ID: mdl-24927608

ABSTRACT

UNLABELLED: BACKGROUND AND RATIONALE OF THE STUDY: Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in real-life cohorts. Our aim was to evaluate the impact of liver fibrosis and other variables on HCC incidence in this population of patients. Of 745 patients with chronic hepatitis B (CHB), 306 HBeAg-negative genotype D were selected and included in this study. All patients received treatment with NUC for at least 18 months. Patients with CHB or compensated cirrhosis were included. Patients with HCC diagnosed before or during the first 18 months of NUC therapy were excluded. RESULTS: HCC was diagnosed in 2 CHB patients (1.0%) and 23 cirrhosis patients (20%) (OR = 24.41, 95% CI 5.40 < OR < 153.2; p < 0.0001). Multivariate analysis revealed that HCC risk was independently associated with age ≥ 60 years (OR = 6.45, 95% CI 1.22 to 34.0; p = 0.02) and liver cirrhosis (OR = 12.1, 95% CI 1.39 to 106.2; p = 0.02), but not with virological response (VR), and previous resistance to NUC, or rescue therapy. Multivariate analysis in cirrhosis patients revealed that only age ≥ 60 years was an independent risk factor associated with HCC (p = 0.003). CONCLUSIONS: Liver cirrhosis and age ≥ 60 years are the stronger risk factors for HCC in genotype D HBeA-gnegative patients. Previous resistance to NUC in patients that achieved a VR after rescue therapy was not a predictive factor regarding HCC. VR does not appear to significantly reduce the overall incidence of HCC when a patient has already progressed to liver cirrhosis.


Subject(s)
Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/etiology , Hepatitis B, Chronic/drug therapy , Liver Neoplasms/etiology , Adenine/analogs & derivatives , Adenine/therapeutic use , Adult , Aged , Cohort Studies , DNA, Viral/genetics , Female , Guanine/analogs & derivatives , Guanine/therapeutic use , Hepatitis B e Antigens/immunology , Hepatitis B virus/genetics , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/immunology , Humans , Lamivudine/therapeutic use , Longitudinal Studies , Male , Middle Aged , Organophosphonates/therapeutic use , Retrospective Studies , Telbivudine , Tenofovir , Thymidine/analogs & derivatives , Thymidine/therapeutic use , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL